专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240131110A1 BONE DISEASE TREATMENT 审中-公开
公开(公告)号：US20240131110A1
公开(公告)日：2024-04-25
申请号：US18488234
申请日：2023-10-16
申请人： The University of Birmingham
发明人： George Edward Rainger , Helen McGettrick , Myriam Chimen
IPC分类号： A61K38/10 , A61K35/32 , A61P19/00 , A61P19/10
CPC分类号： A61K38/10 , A61K35/32 , A61P19/00 , A61P19/10
摘要： The present invention concerns methods of reducing bone loss and/or stimulating bone production comprising administering an effective amount of a peptide comprising the amino acid sequence SVTEQGAELSNEER (SEQ ID NO:1), or variants thereof, to a patient and/or bone cells. The present invention also concerns methods of treatment and/or prophylaxis of musculoskeletal loss and/or damage in a patient, comprising administering an effective amount of the peptide.

2. 发明公开

US20240076674A1 Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors 审中-公开
公开(公告)号：US20240076674A1
公开(公告)日：2024-03-07
申请号：US18334636
申请日：2023-06-14
申请人： Regeneron Pharmaceuticals, Inc. , University of Maryland, Baltimore
发明人： Da-Wei Gong , Nehal Gosalia , Alan Shuldiner , Cristopher Van Hout , James Perry
IPC分类号： C12N15/113 , A61P19/10 , C12Q1/6874
CPC分类号： C12N15/1137 , A61P19/10 , C12Q1/6874
摘要： The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.

3. 发明授权

US11896645B2 Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions 有权
公开(公告)号：US11896645B2
公开(公告)日：2024-02-13
申请号：US17177614
申请日：2021-02-17
申请人： UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
发明人： Stefan Franz Thomas Weiss , Boitelo Theresiah Letsolo , Kerrilyn Naidoo , Tyrone Chad Otgaar
IPC分类号： A61K38/17 , C12N15/113 , C07K14/705 , A61P17/06 , A61P21/00 , A61P9/10 , A61P39/00 , A61P3/10 , A61P35/04 , A61P19/10 , A61K39/395 , C07K16/28
CPC分类号： A61K38/177 , A61K39/395 , A61P3/10 , A61P9/10 , A61P17/06 , A61P19/10 , A61P21/00 , A61P35/04 , A61P39/00 , C07K14/70546 , C07K16/28 , C12N15/113 , C12N2310/14
摘要： The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cancer and cellular ageing. Particularly, herein is disclosed 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in the treatment and/or prevention of cellular ageing.

4. 发明授权

US11872311B2 Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders 有权
公开(公告)号：US11872311B2
公开(公告)日：2024-01-16
申请号：US16800855
申请日：2020-02-25
申请人： The University of North Carolina at Chapel Hill
发明人： Wenbin Lin , Demin Liu , Joseph Della Rocca , Stephanie Kramer , Christopher Y. Poon
IPC分类号： A61K47/69 , A61K9/14 , A61K9/00 , A61K9/51 , A61P19/10 , A61P19/08 , A61K31/663 , A61K49/00 , A61K9/127 , A61K47/54 , A61P35/00 , A61K31/675 , A61K51/12
CPC分类号： A61K9/127 , A61K9/0019 , A61K9/14 , A61K9/5115 , A61K9/5123 , A61K9/5146 , A61K31/663 , A61K31/675 , A61K47/548 , A61K47/6925 , A61K47/6929 , A61K49/00 , A61K51/1244 , A61P19/08 , A61P19/10 , A61P35/00
摘要： Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.

5. 发明授权

US11813308B2 Treatment of cardiovascular disease using ActRII ligand traps 有权
公开(公告)号：US11813308B2
公开(公告)日：2023-11-14
申请号：US15517782
申请日：2015-10-08
申请人： CELGENE CORPORATION , WASHINGTON UNIVERSITY
发明人： Keith Hruska , Yifu Fang , William Smith , Nianhang Chen
IPC分类号： A61K38/17 , A61K38/00 , C07K14/71 , A61P9/10 , A61P9/00 , A61P19/10
CPC分类号： A61K38/179 , A61P9/00 , A61P9/10 , A61P19/10 , C07K14/71 , A61K38/00 , C07K2319/30
摘要： Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor. Provided herein are methods of bone resorption in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), c-terminal telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.

6. 发明公开

US20230321199A1 USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK 审中-公开
公开(公告)号：US20230321199A1
公开(公告)日：2023-10-12
申请号：US18320638
申请日：2023-05-19
申请人： Radius Health, Inc.
发明人： Gary Hattersley
IPC分类号： A61K38/29 , A61P19/08 , A61P19/10 , A61K9/00 , A61K45/06
CPC分类号： A61K38/29 , A61P19/08 , A61P19/10 , A61K9/0019 , A61K45/06
摘要： Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures. Also disclosed are PTHrP or analogues thereof, such as abaloparatide, for increasing BMD and/or TBS in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to increase BMD and/or TBS.

7. 发明公开

US20230285578A1 PTH ANALOGS FOR THE TREATMENT OF HYPOPARATHYROIDISM 审中-公开
公开(公告)号：US20230285578A1
公开(公告)日：2023-09-14
申请号：US17925477
申请日：2021-05-25
申请人： INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
发明人： Richard D. DIMARCHI , Fa ZHANG
IPC分类号： A61K47/64 , C07K14/635 , A61K9/20 , A61P5/18 , A61P19/10
CPC分类号： A61K47/64 , A61K9/20 , A61P5/18 , A61P19/10 , C07K14/635
摘要： A novel derivative of parathyroid hormone is provided that has an extended time of action relative to known native parathyroid hormone agonist peptides, while minimizing excessive action shortly after administration. Compositions comprising the novel parathyroid hormone conjugates can be used to treat hypoparathyroidism and osteoporosis.

8. 发明授权

US11752106B2 Pharmaceutical composition and administrations thereof 有权
公开(公告)号：US11752106B2
公开(公告)日：2023-09-12
申请号：US17475622
申请日：2021-09-15
申请人： Vertex Pharmaceuticals Incorporated
发明人： Eleni Dokou , Shahla Jamzad , John P. Caesar, Jr. , Majed Fawaz , Laura Das , Chong-Hui Gu , Patricia Nell Hurter , Meghna Jai Israni , Meghan M. Johnston , Dragutin Knezic , Andrew G. Kuzmission , HongRen Wang
IPC分类号： A61K9/20 , A61K9/14 , A61K9/16 , A61K9/48 , A61K31/47 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/38 , C07D215/56 , A61P1/10 , A61P1/16 , A61P1/18 , A61P3/00 , A61P3/06 , A61P3/10 , A61P3/12 , A61P5/00 , A61P5/14 , A61P5/16 , A61P5/18 , A61P7/00 , A61P7/04 , A61P7/10 , A61P7/12 , A61P9/00 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/02 , A61P13/12 , A61P15/08 , A61P15/10 , A61P17/00 , A61P19/08 , A61P19/10 , A61P21/00 , A61P21/02 , A61P21/04 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/20 , A61P25/22 , A61P25/28 , A61P27/02 , A61P27/04 , A61P29/00 , A61P31/10 , A61P35/00 , A61P37/06 , A61P37/08 , A61P43/00 , A61K47/00
CPC分类号： A61K9/205 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/485 , A61K9/4808 , A61K9/4858 , A61K9/4866 , A61K31/47 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/38 , C07D215/56
摘要： The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

9. 发明公开

US20230277486A1 COMPOSITIONS FOR THE TREATMENT OF NON-ARTICULAR CARTILAGE-ASSOCIATED BONE CONDITIONS 审中-公开
公开(公告)号：US20230277486A1
公开(公告)日：2023-09-07
申请号：US18316945
申请日：2023-05-12
申请人： Lanny Leo Johnson
发明人： Lanny Leo Johnson
IPC分类号： A61K31/192 , A61P19/10 , A61K35/28 , C12N5/077 , A61L27/38 , A61L27/54 , A61K31/59 , A61K31/122 , A61K33/06
CPC分类号： A61K31/192 , A61P19/10 , A61K35/28 , C12N5/0654 , A61L27/3834 , A61L27/54 , A61K31/59 , A61K31/122 , A61K33/06 , A61L2300/43 , C12N2501/999 , A61L2430/02 , A61L2300/21 , A61L2300/414
摘要： An enhanced bone graft product includes a host matrix, a bone graft material, a scaffold, or a biological construct, and a composition including a therapeutically effective amount of protocatechuic acid. The bone graft material may be autographic, allographic, alloplastic, or xenographic. The bone graft material may include fresh bone, freeze-dried bone, or demineralized freeze-dried bone. The composition may include a pharmaceutically acceptable carrier, adjuvant, or vehicle. The composition may include protocatechuic acid at a concentration of about 10 μM to about 250 μM. The composition may further include mesenchymal stem cells, adipose tissue-derived stem cells, endothelial progenitor cells, mesenchymal skeletal stem cells, synovial stem cells, bone marrow extract, osteoblasts, chondrocytes, osteocytes, or combinations thereof.

10. 发明公开

US20230256052A1 METHOD AND COMPOSITION FOR REDUCING OR PREVENTING BONE RESORPTION 审中-公开
公开(公告)号：US20230256052A1
公开(公告)日：2023-08-17
申请号：US18012288
申请日：2021-07-07
申请人： University of Connecticut
发明人： Tannin Avery Schmidt , Joseph Lorenzo , Sun-Kyeong Lee , Adam Tanguay
IPC分类号： A61K38/17 , A61P19/10 , A61K47/69
CPC分类号： A61K38/1709 , A61P19/10 , A61K47/6903
摘要： An anti-osteoclastic composition containing a proteoglycan 4 in a pharmaceutically acceptable carrier is administered to a human or animal suffering from a pathological bone condition such as osteoporosis in a sufficient amount to reduce, delay onset of or prevent excessive bone resorption in which the rate of bone resorption exceed the rate of bone formation. Excessive bone resorption is inhibited by preventing the formation or activity of osteoclasts. Osteoporosis is linked to bone fracture, a debilitation condition often resulting in the need for risky, invasive surgery, and the possible consequence of permanent immobilization, especially in elderly populations.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式